Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Hexarelin | Sermorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection. | Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection. |
| Timing | On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization. | Bedtime administration (aligns with natural nocturnal GH release). On empty stomach. |
| Cycle Duration | 4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs. | 12-24 week cycles. Some protocols use continuous treatment. |
| Evidence Level | moderate_human | strong_human |
Hexarelin (Examorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent synthetic GH secretagogue by peak GH release. It stimulates GH release through both pituitary ghrelin receptors and hypothalamic pathways, with mechanisms involving regulation of GHRH and somatostatin. Hexarelin also demonstrates significant cardiac benefits through activation of cardiac GHS-R1a receptors, protecting against ischemia-reperfusion injury and reducing cardiac fibrosis via the CD36 scavenger receptor pathway.
Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection.
On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization.
4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs.
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.
Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
12-24 week cycles. Some protocols use continuous treatment.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →